None listed
Conditions
Interventions
Medical Device : The participants assigned to the treatment group will receive acupuncture treatment at 4 acupuncture points (GB20, LI11, ST36, SP6) for 4 weeks (a total of 10 sessions). The participa
Sponsors
Korea Institute of Oriental Medicine
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Women aged 45 to 65 years 2. Menstruation ended 1 year or longer prior to the study 3. Resting blood pressure measured during screening is in the prehypertension stage (systolic blood pressure (SBP) of 120–139 mmHg or diastolic blood pressure (DBP) of 80–89 mmHg) or at stage 1 hypertension (SBP of 140–159 mmHg or DBP of 90–99 mmHg) 4. Provide consent to participate in this trial and sign an informed consent statement after listening to a clear explanation of the purpose and characteristics of this clinical trial
Exclusion criteria
Exclusion criteria: 1. Received antihypertensive drugs, herbal medication or functional food used for hypertension, herbal tea such as persimmon leaf tea within the past 1 months 2. Received hormone therapy, such as estrogen or progestin, herbal medication or functional food used for involutional disorder in the past 1 month 3. History of secondary hypertension or are suspected of secondary hypertension (for example, coarctation of the aorta, renal artery stenosis, primary aldosteronism, pheochromocytoma, Cushing’s syndrome, polycystic renal disease, hyperthyroidism 4. Orthostatic hypotension and accompanying symptoms 5. Uncontrolled diabetes mellitus 6. Severe heart disease, ischemic heart disease during the recent 6 months (angina pectoris, myocardial infarction), or peripheral vascular disease, or have received percutaneous transluminal coronary angioplasty or a coronary artery bypass graft 7. Hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease, aortostenosis, or hemodynamically significant aortic or mitral valve stricture 8. Severe cerebrovascular disease, or have experienced a cerebral infarction or cerebral hemorrhage within the past 6 months 9. Moderate or malignant retinosis, retinal hemorrhage, visual disturbance, or retinal microaneurysm within the past 6 months 10. Consumptive disease (tuberculosis, malignant tumors) or autoimmune disease (systemic lupus erythematosus, rheumatoid arthritis, dermatomyositis, systemic sclerosis, or thyroiditis) 11. Clinically significant kidney or liver disease 12. Confirmed or suspected history of drug or alcohol abuse 13. Chronic inflammatory conditions that require chronic anti-inflammatory treatment 14. Currently participating in other clinical trials 15. Currently an inmate at a group facility, such as a social welfare institution 16. Did not provide informed consent 17. Anyone considered inappropriate for participating in this trial by the clinical trial conductors
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 24 hours average diastolic blood pressure | — |
Secondary
| Measure | Time frame |
|---|---|
| 24 hours average diastolic blood pressure;Day and night average diastolic blood pressure;24 hours and day and night average systolic blood pressure;24 hours mean arterial pressure;24 hours average pulse pressure;Systolic and diastolic blood pressure measured by mercury sphygmomanometer | — |
Countries
Korea, Republic of
Contacts
Public ContactJin-Bong Choi
Dongshin University Gwangju Oriental Hospital
Outcome results
None listed